Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01431287 · ClinicalTrials.gov registry record · Phase 3
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,539
- Enrollment target
NCT01431287 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 2,539 participants.
The verdict
NCT01431287, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,539 participants
- Enrollment target
Study Summary
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components (tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patients with COPD.
Interventions
- DRUG tiotropium + olodaterol
- DRUG tiotropium
- DRUG olodaterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,539 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01431287
The ClinicalTrials.gov registry entry for NCT01431287 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,539 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which tiotropium + olodaterol is the first listed.
NCT01431287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01431287 about?
NCT01431287 is a clinical study titled "Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)". The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components (tiotropium, olodaterol) (delivered by the RESPIMAT Inhaler) in patien...
What is the current status of trial NCT01431287?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,539 participants. The study started on 2011-09. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01431287?
The interventions under investigation include: tiotropium + olodaterol (DRUG), tiotropium (DRUG), olodaterol (DRUG).
Who is sponsoring clinical trial NCT01431287?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.